Analytical Data
-
Gene name
FUCA1
- Application
-
Alternative Names
A-FU; aFU; Alpha-L-Fucosidase; Alpha-L-fucoside fucohydrolase 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04066
-
Expression Region
Phe53~Pro289
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FUCA1 (fucosidase alpha L-fucosidase) is an essential enzyme involved in the metabolism of fucose, a hexose deoxy sugar that plays a critical role in various biological processes, including cell signaling, immune response, and pathogen recognition. Mutations in the FUCA1 gene are associated with fucosidosis, a rare lysosomal storage disorder characterized by neurological deficits and skeletal anomalies. The study of FUCA1 recombinant protein serves multiple purposes: it aids in understanding enzyme structure-function relationships, facilitates investigations into the metabolic pathways involving fucose, and supports the development of potential therapeutic strategies for fucosidosis. By producing FUCA1 in a recombinant system, researchers can obtain large quantities of the enzyme, allowing for detailed biochemical characterization, crystallization studies, and the assessment of its activity under various conditions. Furthermore, this approach enables the generation of specific antibodies and inhibitors that can be utilized in diagnostic applications or as potential treatments. The exploration of FUCA1 not only enhances our comprehension of fucose metabolism but also opens avenues for therapeutic interventions targeting related disorders, thereby contributing to the broader field of glycobiology and personalized medicine.
